Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Charmin Broughton

Nurse Practitioner, Family Parker, CO Nurse Practitioner

NPI 1144634734 CMS profile 10953479

16830 Northgate Dr, Ste 130, Parker, CO 80134

Open in the dashboard

General payments

$11,436

344 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charmin Broughton of Parker, CO is reported in the CMS Open Payments database as having received $11,436 across 344 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,178 93
2024 General $2,165 84
2023 General $2,759 97
2022 General $1,436 52
2021 General $898 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charmin Broughton
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Charmin Broughton were reported at $4,178. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Charmin Broughton Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $898 $124 $35–$379 $132
2022 $1,436 $141 $44–$430 $149
2023 $2,759 $154 $49–$476 $160
2024 $2,165 $165 $51–$504 $164
2025 $4,178 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Saluda Medical Americas, Inc. $2,502 13 payments
  2. Boston Scientific Corporation $1,867 30 payments
  3. AbbVie, Inc. $1,348 67 payments
  4. Lundbeck LLC $741 26 payments
  5. Collegium Pharmaceutical, Inc. $600 44 payments
  6. Relievant Medsystems, Inc. $549 5 payments
  7. Scilex Pharmaceuticals Inc. $453 28 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $430 22 payments
  9. Pfizer Inc. $429 23 payments
  10. Biohaven Pharmaceuticals, Inc. $406 8 payments
  11. Other $2,112 78 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,638 341 payments
  2. Travel and Lodging $1,798 3 payments
Products named General payments · program years 2021–2025
  1. Evoke $2,502 13 payments
  2. QULIPTA $1,007 55 payments
  3. UBRELVY $877 30 payments
  4. General - Pain Management $677 8 payments
  5. Intracept Pain $671 6 payments
  6. NURTEC ODT $593 14 payments
  7. Intracept Pain $549 5 payments
  8. Intracept Pain $549 5 payments
  9. Intracept Pain $549 5 payments
  10. ZTLido $435 27 payments
  11. Other $5,325 243 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

3,524

Median for Nurse Practitioner: 389

Drug cost

$249,755

Median for Nurse Practitioner: $21,885

Branded share of claims

28.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 66 $42,255
Oxycontin Oxycodone Hcl Brand 51 $26,925
Belbuca Buprenorphine Hcl Brand 33 $25,126
Buprenorphine Generic 68 $17,475
Ubrelvy Ubrogepant Brand 17 $16,112
Oxycodone Hcl Generic 755 $15,979
Movantik Naloxegol Oxalate Brand 36 $13,529
Aimovig Autoinjector Erenumab-Aooe Brand 16 $12,011
Fentanyl Generic 67 $10,983
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 298 $10,816

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$19,310

Of which drugs: $51

Medicare patients

95

Average age 66

Services billed

354

64 women, 31 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 69%
Depression 47%
Diabetes 26%
COPD 25%
Osteoporosis 23%
Heart failure 21%
Ischemic heart disease 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 73 $51

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $197
$197 — —
VYEPTI
  • Lundbeck LLC $195
$195 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $157
$157 — —
QULIPTA
  • AbbVie, Inc. $145
$145 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $110
$110 66 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

344 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record